The big picture: Lauxera Capital Partners has closed its second healthtech growth fund, Lauxera Growth II, at €520 million, exceeding its €500 million hard cap. This nearly doubles the size of its first fund, bringing the firm’s total assets under management to over €1 billion.
Why it matters:
- Oversubscribed Fund: Lauxera Growth II was oversubscribed and closed in less than 18 months, with over 90% of existing limited partners reinvesting and attracting new investors from diverse international regions.
- Proven Strategy: The firm’s investment approach was validated by the October 2025 acquisition of its UK portfolio company, OrganOx, by Japan’s Terumo Group for approximately $1.5 billion.
- European Innovation Focus: Lauxera targets European healthtech companies, leveraging the region’s high innovation per capita in areas like medtech, bioprocessing, and imaging, with a strategic focus on helping these innovations succeed in the US market.
How it works:
- Investment Scope: Lauxera Growth II plans to invest €20-€50 million in 12 to 15 European healthtech companies, taking both minority and majority stakes across medical devices, digital health, pharma services, and life science tools.
- Thematic Sourcing: The firm employs a thematic deal-sourcing approach, identifying 2-3 focus areas annually, conducting competitive analysis, and directly engaging companies to secure exclusivity before formal evaluations.
- Rigorous Criteria: Investment decisions are based on four key factors: clinical need and technology defensibility, business model sustainability, a strong competitive edge, and the ability for the company to succeed outside its home market.
The catch: While Lauxera highlights its differentiated strategy against peers like MTIP and SHS, the competitive landscape for European healthtech growth equity remains intense. Successfully translating European innovation to US market dominance requires significant operational expertise and navigating complex regulatory and commercial hurdles.
Key Facts
- Company: Lauxera Capital Partners
- Amount: €520M
- Round: Growth Fund II
- Founders: Pierre Moustial, Samuel Levy, Alex Slack
- Sector: Healthtech
